Investigational drug · Phase 2
SHR-1139
Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Moderate to Severe Plaque Psoriasis, Palmoplantar Pustulosis of Adults, Pyoderma Gangrenosum.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
5
5 still active
All registered trials
9
Any phase or sponsor naming "SHR-1139"
First trial start
2025
Mar 28, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SHR-1139", any sponsor or status.
Conditions studied
As listed on its trial records.
- Moderate to Severe Plaque Psoriasis
- Palmoplantar Pustulosis of Adults
- Pyoderma Gangrenosum
- Adult Patients With Moderately to Severely Active Ulcerative Colitis
- Plaque Psoriasis
Approved drugs for the same conditions: Plaque psoriasis · Ulcerative colitis · Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "SHR-1139" as an intervention, largest first.
- A Trial Comparing SHR-1139 Injection With Placebo in Patients With Moderate-to-severe Plaque PsoriasisPivotal-lookingActive, not recruiting
Guangdong Hengrui Pharmaceutical Co., LtdIndustry
NCT06875934 · 145 participants · Start Mar 28, 2025 · Primary completion Nov 2025
Drug: SHR-1139 Injection; SHR-1139 Injection Placebo · For: Moderate to Severe Plaque Psoriasis
Sites: Shanghai, China
Guangdong Hengrui Pharmaceutical Co., LtdIndustry
NCT07051538 · 64 participants · Start Jun 26, 2024 · Primary completion Nov 28, 2025
Drug: SHR-1139 Injections; SHR-1139 Injections Placebo · For: Moderate to Severe Plaque Psoriasis
Sites: Shanghai, China
Guangdong Hengrui Pharmaceutical Co., LtdIndustry
NCT07719530 · 60 participants (planned) · Start Aug 4, 2026 · Primary completion Dec 31, 2026
Drug: The SHR-1139 injection; placebo · For: Psoriasis
Sites: Guangzhou, China
- A Phase II Clinical Study to Evaluate the Efficacy and Safety of SHR-1139 Injection in Patients With Plaque PsoriasisNot yet recruiting
Guangdong Hengrui Pharmaceutical Co., LtdIndustry
NCT07758075 · 50 participants (planned) · Start Aug 2026 · Primary completion Jul 2027
Drug: SHR-1139; SHR-1139 and SHR-1139 pleacebo · For: Plaque Psoriasis
Sites: Changsha, China
- A Trial Evaluating the Efficacy and Safety of SHR-1139 Injection in Adult Patients With Palmoplantar PustulosisNot yet recruiting
Guangdong Hengrui Pharmaceutical Co., LtdIndustry
NCT07923851 · 40 participants (planned) · Start Nov 2026 · Primary completion Nov 2027
Drug: SHR-1139 Injection; SHR-1139 Injection Placebo · For: Palmoplantar Pustulosis of Adults
Sites: Guangzhou, China; Xi’an, China
- A Trial of SHR-1139 in Healthy VolunteersActive, not recruiting
Atridia Pty Ltd.Industry
NCT07078695 · 24 participants (planned) · Start Aug 19, 2025 · Primary completion Nov 9, 2026
Drug: SHR-1139 Injection; SHR-1139 Injection and 1 more · For: Psoriasis
Sites: Perth, Australia
- A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of SHR-1139 in Patients With Moderate-to-severe Active Ulcerative ColitisActive, not recruiting
Guangdong Hengrui Pharmaceutical Co., LtdIndustry
NCT07232576 · 21 participants · Start Dec 1, 2025 · Primary completion Aug 2027
Drug: SHR-1139 intravenous injection. · For: Adult Patients With Moderately to Severely Active Ulcerative Colitis
Sites: Guangzhou, China
Guangdong Hengrui Pharmaceutical Co., LtdIndustry
NCT07444684 · 20 participants (planned) · Start Mar 5, 2026 · Primary completion Jun 2027
Drug: SHR-1139 Injection · For: Pyoderma Gangrenosum
Sites: Jinan, China
Shandong First Medical UniversityAcademic, hospital or other
NCT07337564 · 10 participants (planned) · Start Jan 29, 2026 · Primary completion Dec 2027
Drug: SHR-1139 Injection · For: Pyoderma Gangrenosum
Sites: Jinan, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Moderate to Severe Plaque Psoriasis
- CMS-D001Phase 32 trials
Dermavon Holdings Limited · Moderate to Severe Plaque Psoriasis, Moderate to Severe Atopic Dermatitis
- SYHX1901Phase 32 trials
CSPC Ouyi Pharmaceutical Co., Ltd. · Moderate to Severe Plaque Psoriasis, Severe Alopecia Areata
- WD-890Phase 32 trials
Zhejiang Wenda Pharma Technology LTD. · Brief Description of Focus of Study, Moderate to Severe Plaque Psoriasis
- HS-20118Phase 21 trial
Jiangsu Hansoh Pharmaceutical Co., Ltd. · Moderate to Severe Plaque Psoriasis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.